Mouth ulcer

The geko™ device is now available through the NHS Supply Chain

Retrieved on: 
Wednesday, May 1, 2024
Leg, Supply, Pain, Patient, Knee, Cancer, BMJ Open, NHS, Acceleration, Calf, DOI, Hope, National Health Service, Hospital, Skin, PMID, SOC, Recurrence, Common fibular nerve, Carbon, INT, IWJ, Quality-adjusted life year, Mouth ulcer, Nursing, Health, Cardiovascular disease, Standard of care, Wound healing, RCT, Life imprisonment, Quality of life, Anxiety

HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain. The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.

Key Points: 
  • HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain .
  • The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.
  • "We're delighted to be listed on the NHS Supply Chain," said Bernard Ross, CEO and Founder of Sky Medical Technology.
  • Now with this wider access, through the NHS Supply Chain, geko device ease of ordering will further help NHS wound care nurses reduce the time managing wounds."

"A New Era in Venous Care: Bowie Welcomes Vein Treatment Clinic"

Retrieved on: 
Tuesday, April 30, 2024
Radiofrequency ablation, Mouth ulcer, Patient, RFA, Swelling, Education, Vein, Oberlin College, Itch, Varicose veins, Female, Environment, Physician, Weight, Cramp, General surgery

BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.

Key Points: 
  • BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.
  • Vein Treatment Clinic is dedicated to the comprehensive management and treatment of various venous disorders, including varicose veins, spider veins, venous ulcers, and more.
  • Per Dr. Kamran Saraf, "At the Vein Treatment Clinic, we are committed to excellence in vein care with minimal discomfort or downtime."
  • For additional information about the Vein Treatment Clinic or to book a consultation, please visit www.veintreatmentclinic.com or contact the clinic directly at 240-219-8778.

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, Chronic venous insufficiency, Patient, Mouth ulcer, Journal, JWC, Wound healing, Safety, CVI, Trial of the century

The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.

Key Points: 
  • The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.
  • All the patients in the study had failed to respond favorably to prior standard of care wound treatment.
  • The findings from this multicenter clinical study have been published in the March addition of the peer reviewed Journal of Wound Care (JWC).
  • Merakris also will present a poster at the JWC- sponsored CAMPs (Cellular Acellular and Matrix-Like Products) Wound Care Summit in Miami, Florida, March 13-14.

FibroBiologics to Present at Advanced Wound Care Summit USA

Retrieved on: 
Wednesday, March 13, 2024
Mouth ulcer, Fibroblast, Risk, Communication, Form, Conditional sentence, MD, Wound healing, Therapy, Pharmaceutical industry

The Advanced Wound Care Summit USA is a forum where industry leaders share the latest innovations and advancements in Wound Care and tackle pressing challenges in areas such as regulation, clinical trials, reimbursement, and investment.

Key Points: 
  • The Advanced Wound Care Summit USA is a forum where industry leaders share the latest innovations and advancements in Wound Care and tackle pressing challenges in areas such as regulation, clinical trials, reimbursement, and investment.
  • FibroBiologics will be represented by Chief Scientific Officer, Hamid Khoja, Ph.D., and Associate Scientist, Subhiksha Raghuram, MS, MD, who will present on FibroBiologics' fibroblast cell therapies and their potential to treat chronic wounds.
  • We believe that by harnessing the specific capacity of fibroblasts in wound healing, we have the potential of revolutionizing wound care as we know it.
  • For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected] .

SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal

Retrieved on: 
Monday, March 4, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, VLU, Doctor of Philosophy, Nature Reviews Disease Primers, MD, Wound healing, MBA, INN, University, Safety, Mouth ulcer, Element, Debridement, Patient, Phase, Infection, Human, Medical device

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.

Key Points: 
  • SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.
  • The Phase IIa data, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been peer-reviewed and published, providing strong validation as SolasCure progresses into further clinical studies, and marks a significant milestone for the Company.
  • SolasCure’s CLEANVLU Phase IIa trial was performed in venous leg ulcer (VLU) patients across centers in the US, UK, and Hungary.
  • The trial compared five escalating dose concentrations to baseline the use of tarumase for enzymatic debridement and wound bed preparation.

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Retrieved on: 
Friday, February 2, 2024
Partnership, Conjunctivitis, Medicine, Inflammation, Vitamin, Thrombocytopenia, Immune system, Tyrosine, Patient, Light, Nosebleed, Intellectual disability, Itch, Ageing, Diet, Keratitis, Skin, Pharmacy, Tongue, Rash, DSM-IV codes, Allergy, Blood, Leukopenia, Photophobia, Mouth ulcer, Phenylalanine, Erythroderma, Tell, Insurance, Face, Breast milk, Plasma, Nursing

DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Key Points: 
  • We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual Nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • Nitisinone Capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
  • Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Regeneron Pharmaceuticals, Mouth ulcer, Patient, European, Conjunctivitis, Eosinophilia, Foot, Blepharitis, Keratitis, Walking, Aes, Skin, Food, Safety, Human, Inflammation, FDA, Physician, Bleeding, Atopic dermatitis, International development, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement. These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.

Key Points: 
  • These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.
  • “Having these data added for this difficult-to-treat population is important for physicians looking for tools to treat these patients and reinforces the already well-established efficacy and safety of Dupixent in atopic dermatitis overall.”
    The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial.
  • In the trial, patients received Dupixent (n=67) every two weeks (adults 300 mg, adolescents 200 mg or 300 mg based on body weight) or placebo (n=66).
  • Most common adverse events (AEs) observed with Dupixent (≥1%) in atopic dermatitis include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye and eosinophilia.

Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24

Retrieved on: 
Thursday, January 4, 2024
Janus, Commercialization, OD, Drug development, Completeness, CMO, Hepatocyte growth factor, Master of Science, Novo Holdings A/S, Ear, MD, Neurotrophic factors, Nerve, Mass, Burns (surname), Mouth ulcer, Perforation, Ulcer, Series, Scar, MPH, Patient, NK, Medical imaging

Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.

Key Points: 
  • Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.
  • Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea.
  • Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024.
  • Additional indications of interest that are being actively pursued by Claris, supported by preclinical and clinical data, include limbal stem cell deficiency and pre-existing corneal scar.

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Constipation, INN, Leukopenia, Woman, Carcinoma, Lung cancer, Fatigue, Nausea, DNA, Cancer, Neoplasm, Infection, SCLC, Mouth ulcer, Risk management, Anatomy, Paclitaxel, IIA, CHMP, Diarrhea, Fever, ATC, Capsule, European, Disease, Weakness, Mucositis, Anemia, Medical Subject Headings, Febrile neutropenia, European Commission, Cyclophosphamide, Vincristine, International, Neutropenia, Somatic symptom disorder, Aplastic anemia, Language, Cisplatin, Thrombocytopenia, Medication, Select, Patient, Medicine, Vomiting, Ovary, Survival, Ovarian cancer, Cervical cancer, Hair loss, Radiation, Doxorubicin, Committee, Medical device

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024
SCD, Medical Subject Headings, Marketing, Febrile neutropenia, European Commission, Sickle cell disease, INN, Limited, Hematology, Physician, ATC, EMA, B cell, International, ATMP, HLA, Vomiting, Headache, Thalassemia, Nausea, Tissue, Disease, Civil service commission, HSC, CD34, Cas9, Haematopoiesis, Vertex Pharmaceuticals, Public, Gene, Transplant, Medication package insert, Volatile organic compound, Committee, Patient, Liver disease, TDT, HBF, Mouth ulcer, Cell, Anatomy, Medicine, Hemoglobinopathy, BCL11A, Health, CHMP

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Key Points: 


Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion